Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
By T. Erkinjuntti, A. Kurz, S. Gauthier, R. Bullock, S. Lilienfeld, C. Damaraju. 2002
693 citations recorded by the source corpus.
Subfields: Molecular Biology, Neurology, Organic Chemistry
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Neurology
Citations in the corpus
- Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007, result): “significant in the probable VaD sub-group [206].”
- Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “Galantamine has a significant therapeutic effect in the management of patients with Alzheimer’s disease (Erkinjuntti et al., 2008; Erkinjuntti et al., 2002; Kaduszkiewicz et al., 2005; Kavirajan and Schneider, 2007; Loy and Schneider, 2006; Raskind et al., 2000; Tariot et al., 2000; Wilcock et al.,…”
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, methodology): “All but 3 of the studies (43, 45, 47) included only patients with Alzheimer disease.”
- Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force (2003, background): “One systematic review found that aspirin had no effect on cognitive symptoms in people with vascular dementia(93); 1 RCT found that nimodipine (a calcium channel blocker) had no effect on the cognitive and the global symptoms of patients with vascular dementia,(92) and 1 RCT found that galantamine a”
- Acetylcholinesterase inhibitors from plants. (2007, background): “…plant derived inhibitors of AChE has accelerated in view of the benefits of these drugs not only in the treatment of AD but in other forms of dementia, such as dementia with Lewy bodies (Perry et al., 1994 ), vascular dementia (Erkinjuntti et al., 2002) and Down's syndrome (Kishnani et al., 1999).”